financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Maintains Buy Opinion On Shares Of Pvh Corp.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Maintains Buy Opinion On Shares Of Pvh Corp.
Jun 5, 2024 5:32 AM

08:10 AM EDT, 06/05/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We maintain our 12-month price target of $138, based on 12.0x our FY 25 (Jan.) EPS estimate and below the company's 5-year average forward P/E multiple of 13.1x. We maintain our FY 25 and FY 26 EPS estimates of $11.50 and $12.25, respectively. PVH posts normalized Q1 EPS of $2.45 vs. $2.15, $0.26 above consensus estimates on revenues of $1.95B vs. $2.16B and $16M above estimates. By brand in Q1, Tommy Hilfiger revenues declined 10% Y/Y and Calvin Klein sales were flat. By channel, direct-to-consumer revenues increased 1% while wholesale revenues declined 17%. Q1 gross margin increased 350 bps to 61.4% due to a reduction in sales to lower margin wholesale accounts and lower product costs. We believe PVH's full-year guidance is conservative and believe the company's multiple is unfairly lower than many peers with worse margin profiles in apparel retail. With shares trading well under its historical average forward multiple (10.5x), we see plenty of upside.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surge
5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surge
May 8, 2024
Treating America's obesity epidemic is turning into big business. Two pharmaceutical companies, Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) , are leading the weight-loss revolution with a new class of drugs known as GLP-1 agonists. Surging revenue and growing excitement has led some analysts to compare the success of GLP-1 drugs in the health and wellness...
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Trade Desk, Inc.
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Trade Desk, Inc.
May 8, 2024
12:45 AM EDT, 05/09/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our 12-month target at $100, on a P/E of 53.5x our '25 view, above peers but within its 10-year historical forward average. We keep our above consensus '24...
Research Alert: CFRA Lowers Opinion On Shares Of United Parks & Resorts Inc. To Hold From Buy
Research Alert: CFRA Lowers Opinion On Shares Of United Parks & Resorts Inc. To Hold From Buy
May 8, 2024
02:35 AM EDT, 05/09/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We trim our 12-month target to $56 from $61, on 2024 EV/EBITDA of 7.3x, near the low-end of PRKS's long-term trading range of 7x-12x. We lift our 2024 EPS to...
Research Alert: CFRA Maintains Hold Opinion On Shares Of Arm Holdings Plc
Research Alert: CFRA Maintains Hold Opinion On Shares Of Arm Holdings Plc
May 9, 2024
08:05 AM EDT, 05/09/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We adjust our 12-month target to $120 from $140, on a lower revised peer-premium P/E of 64.8x our CY 25 EPS estimate, warranted given our view of growth prospects. We...
Copyright 2023-2026 - www.financetom.com All Rights Reserved